サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566980

ビンカアルカロイド化合物市場：製品タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Vinca Alkaloid Compounds Market By Product Type (Vinblastine, Vincristine, Vindesine) , By End User (Hospitals, Clinics, Academic & Research Institutes) : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
ビンカアルカロイド化合物市場：製品タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ビンカアルカロイド化合物市場

ビンカアルカロイド化合物市場は、2023年に8,100万米ドルと評価され、2024～2033年にかけてCAGR 7.2%で成長し、2033年には1億6,150万米ドルに達すると予測されています。

ビンカアルカロイドは天然に存在する二次代謝産物で、主にシソ科の植物Catharanthus roseusから抽出されます。この化合物は、抗有糸分裂と抗微小管特性のために利用されています。細胞分裂の際、ビンカアルカロイド化合物は、細胞分裂を構造的に支えるのに必要なタンパク質であるβチューブリンの重合を阻害します。この阻害は細胞毒性と細胞死をもたらします。この化合物の特性は、リンパ腫、白血病、乳がん、肺がんなど、さまざまながんの治療アプローチとして利用されています。

様々ながんの有病率の増加と治療の発展が、ビンカアルカロイド化合物市場の重要な促進要因です。さらに、がんを緩和するための治療や治療ソリューションの開発に向けた絶え間ない研究開発努力が、ビンカアルカロイド化合物の需要を押し上げています。内生植物を利用したこの二次代謝物の合成は、今後重要な動向になると予測されています。植物から直接ビンカアルカロイド化合物を抽出するのは、非常に非効率的で複雑です。これとは対照的に、エンドファイトの微生物発酵プロセスは著しく実現可能で有能な手順であり、今後数年間で抗がん剤の生産を促進し、後押しすると予想されています。

しかし、神経毒性や骨髄抑制など、ビンカアルカロイド化合物の潜在的な副作用は深刻です。このため、化合物の使用がある程度制限され、市場の開拓を抑制しています。さらに、ビンカアルカロイド化合物に由来する薬剤は、長期間使用すると腫瘍細胞が耐性を獲得するため、長期的な有効性が低下し、市場開拓の妨げとなります。それとは逆に、市場開拓の技術革新により、ビンカアルカロイド化合物の抗がん作用を利用し、その限界を取り除くことで、市場拡大に有利な機会をもたらしています。例えば、National Library of Medicineに掲載された研究論文によると、ビンカアルカロイド化合物の副作用は、他の化学療法薬と組み合わせる併用療法によって緩和され、カクテル薬の抗腫瘍効果を高めています。

セグメント別レビュー

ビンカアルカロイド化合物市場は、製品タイプ、エンドユーザー、地域に区分されます。製品タイプ別では、市場はビンブラスチン、ビンクリスチン、ビンデシンに分けられます。エンドユーザー別では、病院、クリニック、学術・研究機関に分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

製品タイプ別では、ビンクリスチンセグメントが2023年の市場を独占しました。

エンドユーザー別では、病院セグメントが2023年に高い市場シェアを占めました。

地域別では、北米が2023年に最も高い収益を上げました。

本レポートのカスタマイズの可能性（追加費用とスケジュールが必要です。）

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 ビンカアルカロイド化合物市場：製品タイプ別

  • 市場概要
  • ビンブラスチン
  • ビンクリスチン
  • ビンデシン

第5章 ビンカアルカロイド化合物市場：エンドユーザー別

  • 市場概要
  • 病院
  • クリニック
  • 学術研究機関

第6章 ビンカアルカロイド化合物市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国のビンカアルカロイド化合物市場
    • カナダのビンカアルカロイド化合物市場
    • メキシコのビンカアルカロイド化合物市場
  • 欧州
    • 主要市場動向と機会
    • ドイツのビンカアルカロイド化合物市場
    • フランスのビンカアルカロイド化合物市場
    • 英国のビンカアルカロイド化合物市場
    • イタリアのビンカアルカロイド化合物市場
    • スペインのビンカアルカロイド化合物市場
    • その他の欧州のビンカアルカロイド化合物市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本のビンカアルカロイド化合物市場
    • 中国のビンカアルカロイド化合物市場
    • オーストラリアのビンカアルカロイド化合物市場
    • インドのビンカアルカロイド化合物市場
    • 韓国のビンカアルカロイド化合物市場
    • その他のアジア太平洋のビンカアルカロイド化合物市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルのビンカアルカロイド化合物市場
    • サウジアラビアのビンカアルカロイド化合物市場
    • 南アフリカのビンカアルカロイド化合物市場
    • その他のラテンアメリカ・中東・アフリカのビンカアルカロイド化合物市場

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第8章 企業プロファイル

  • Accord Healthcare Limited
  • Eli Lilly And Company.
  • Fresenius Kabi AG
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Medline Industries, LP.
  • Pfizer Inc.
  • Pierre Fabre S.A
  • Talon Pharmaceuticals
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
目次
Product Code: A324538

Vinca Alkaloid Compounds Market

The vinca alkaloid compounds market was valued at $81.0 million in 2023 and is projected to reach $161.5 million by 2033, growing at a CAGR of 7.2% from 2024 to 2033.

Vinca alkaloid is a naturally occurring secondary metabolite, majorly extracted from the periwinkle plant Catharanthus roseus. The compound is utilized for its anti-mitotic and anti-microtubule properties. During cell division, vinca alkaloid compounds block the polymerization of beta-tubulin, a protein necessary to provide structural support during cell division. This blockage results in cytotoxicity and cell death. This property of the compounds is utilized as a therapeutic approach for the treatment of various cancers, including lymphomas, leukemias, breast cancer, and lung cancer.

Increase in the prevalence of various cancer forms and advancements in the development of therapeutic drugs are the significant drivers of the vinca alkaloid compounds market. Furthermore, constant R&D efforts toward the generation of medications and treatment solutions for the mitigation of cancer boost the demand for vinca alkaloid compounds. The synthesis of this secondary metabolite using endophytes is projected to be a significant trend in the future. Extraction of vinca alkaloid compounds directly from the plant is highly inefficient and intricate. Contrarily, the process of microbial fermentation of endophytes is a notably feasible and competent procedure, which is anticipated to facilitate and boost the production of anti-cancer drugs in upcoming years.

However, the potential side-effects of vinca alkaloid compounds are severe, including neurotoxicity and myelosuppression. This limits the usage of compounds to a certain extent, hence restraining the development of the market. Moreover, the tumor cells develop a resistance to the drugs derived from vinca alkaloid compounds over long durations, lowering their long-term efficacy and hampering the market growth. On the contrary, innovations in drug development have led to the harnessing of anti-cancerous properties of vinca alkaloid compounds by eliminating their limitations, presenting lucrative opportunities for the expansion of the market. For instance, according to a research paper published on the National Library of Medicine, the side-effects of vinca alkaloid compounds are mitigated using combination therapy, in which the compound is combined with some other chemotherapy drug, enhancing the anti-tumor effect of the cocktail drug.

Segment Review

The vinca alkaloid compounds market is segmented into product type, end user, and region. On the basis of product type, the market is divided into vinblastine, vincristine, and vindesine. As per end user, it is classified into hospitals, clinics, and academic & research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the vincristine segment dominated the market in 2023.

As per end user, the hospitals segment accounted for a high market share in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global vinca alkaloid compounds market include Accord Healthcare Limited, Eli Lilly and Company., Fresenius Kabi AG, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Medline Industries, LP., Pfizer Inc., Pierre Fabre S.A, Talon Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Viatris Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Vinblastine
  • Vincristine
  • Vindesine

By End User

  • Hospitals
  • Clinics
  • Academic Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Accord Healthcare Limited
    • Eli Lilly and Company.
    • Fresenius Kabi AG
    • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • Medline Industries, LP.
    • Pfizer Inc.
    • Pierre Fabre S.A
    • Talon Pharmaceuticals
    • Teva Pharmaceutical Industries Limited
    • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VINCA ALKALOID COMPOUNDS MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Vinblastine
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Vincristine
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Vindesine
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: VINCA ALKALOID COMPOUNDS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Clinics
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Academic Research Institutes
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: VINCA ALKALOID COMPOUNDS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Product Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Vinca Alkaloid Compounds Market
      • 6.2.5.1. Market Size and Forecast, By Product Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Vinca Alkaloid Compounds Market
      • 6.2.6.1. Market Size and Forecast, By Product Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Vinca Alkaloid Compounds Market
      • 6.2.7.1. Market Size and Forecast, By Product Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Product Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Vinca Alkaloid Compounds Market
      • 6.3.5.1. Market Size and Forecast, By Product Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Vinca Alkaloid Compounds Market
      • 6.3.6.1. Market Size and Forecast, By Product Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Vinca Alkaloid Compounds Market
      • 6.3.7.1. Market Size and Forecast, By Product Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Vinca Alkaloid Compounds Market
      • 6.3.8.1. Market Size and Forecast, By Product Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Vinca Alkaloid Compounds Market
      • 6.3.9.1. Market Size and Forecast, By Product Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Vinca Alkaloid Compounds Market
      • 6.3.10.1. Market Size and Forecast, By Product Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Product Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Vinca Alkaloid Compounds Market
      • 6.4.5.1. Market Size and Forecast, By Product Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Vinca Alkaloid Compounds Market
      • 6.4.6.1. Market Size and Forecast, By Product Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Vinca Alkaloid Compounds Market
      • 6.4.7.1. Market Size and Forecast, By Product Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Vinca Alkaloid Compounds Market
      • 6.4.8.1. Market Size and Forecast, By Product Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Vinca Alkaloid Compounds Market
      • 6.4.9.1. Market Size and Forecast, By Product Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Vinca Alkaloid Compounds Market
      • 6.4.10.1. Market Size and Forecast, By Product Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Product Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Vinca Alkaloid Compounds Market
      • 6.5.5.1. Market Size and Forecast, By Product Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Vinca Alkaloid Compounds Market
      • 6.5.6.1. Market Size and Forecast, By Product Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Vinca Alkaloid Compounds Market
      • 6.5.7.1. Market Size and Forecast, By Product Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Vinca Alkaloid Compounds Market
      • 6.5.8.1. Market Size and Forecast, By Product Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Accord Healthcare Limited
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Eli Lilly And Company.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Fresenius Kabi AG
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Medline Industries, LP.
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Pfizer Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Pierre Fabre S.A
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Talon Pharmaceuticals
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Teva Pharmaceutical Industries Limited
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Viatris Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments